rs863223406
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000020.3(ACVRL1):c.1377+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,884 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000020.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACVRL1 | NM_000020.3 | c.1377+1G>A | splice_donor_variant, intron_variant | Intron 9 of 9 | ENST00000388922.9 | NP_000011.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461884Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 727244
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Telangiectasia, hereditary hemorrhagic, type 2 Pathogenic:2
- -
This sequence change affects a donor splice site in intron 9 of the ACVRL1 gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is not present in population databases (ExAC no frequency). Disruption of this splice site has been observed in individuals with hereditary hemorrhagic telangiectasia (PMID: 15712270, 19508727, 21158752; Invitae). ClinVar contains an entry for this variant (Variation ID: 212794). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:2
IVS9+1 G>A : c.1377+1 G>A in intron 9 of the ACVRL1 gene (NM_000020.2). The c.1377+1 G>A mutation has been reported previously in association with HHT, and was absent from 100 control alleles (Kuehl H et al., 2005). Furthermore, the c.1377+1 G>A mutation was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. This mutation destroys the canonical splice donor site in intron 9 and is predicted to cause abnormal gene splicing. Other splice site mutations in the ACVRL1 gene have been reported in association with HHT. In summary, c.1377+1 G>A in the ACVRL1 gene is interpreted as a disease-causing mutation. This variant was found in HHT-ARRHYTHMIA panel(s). -
PM2_supporting, PS4_moderate, PVS1 -
Hereditary hemorrhagic telangiectasia Pathogenic:1
This sequence change in ACVRL1 occurs within the canonical splice donor site of intron 9. It is predicted to cause cryptic donor site activation resulting in an in-frame deletion (removes 19 amino acids) that is expected to remove part of the kinase domain which is critical for protein function. This variant is absent from the population database gnomAD v2.1 and v3.1. This variant has been reported in at least three probands meeting a clinical diagnosis of hereditary haemorrhagic telangiectasia (PMID: 15712270, 19508727; Royal Melbourne Hospital). Based on the classification scheme RMH Modified ACMG/AMP Guidelines v1.6.1, this variant is classified as LIKELY PATHOGENIC. Following criteria are met: PVS1_Strong, PM2_Supporting, PS4_Moderate -
Cardiovascular phenotype Pathogenic:1
The c.1377+1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide after coding exon 8 of the ACVRL1 gene. This alteration occurs at the 3' terminus of the ACVRL1 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 87 amino acids of the protein. The exact functional effect of this alteration is unknown; however, the impacted region is critical for protein function (Ambry internal data). This mutation was first reported in a patient with liver involvement who met diagnostic criteria for hereditary hemorrhagic telangiectasia (HHT) (Kuehl HK, Hum. Mutat. 2005 Mar;25:320). This mutation was later reported in a patient with epistaxis, telangiectasias, gastrointestinal arteriovenous malformations, and a family history of HHT (Sadick H, BMC Med. Genet. 2009 Jun 9;10:53). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at